1. Dear Drugs-Forum readers: We are a small non-profit that runs one of the most read drug information & addiction help websites in the world. We serve over 4 million readers per month, and have costs like all popular websites: servers, hosting, licenses and software. To protect our independence we do not run ads. We take no government funds. We run on donations which average $25. If everyone reading this would donate $5 then this fund raiser would be done in an hour. If Drugs-Forum is useful to you, take one minute to keep it online another year by donating whatever you can today. Donations are currently not sufficient to pay our bills and keep the site up. Your help is most welcome. Thank you.
    PLEASE HELP

Quetiapine fumarate augmentation for patients with a primary anxiety disorder or a mood disorder: a

Efficacy of quetiapine in treatment of anxiety disorders

  1. aemetha
    Study Author(s):
    Yi-Chih Chen, Chih-Ken Chen, and Liang-Jen Wang
    Journal Name:
    BMC Psyciatry
    Publication Date:
    2012
    Abstract
    Background: Comorbid anxiety symptoms,in patients with a primary anxiety disorder or a mood disorder, leads to
    poor patient outcomes and burdens the healthcare system. This pilot study evaluated the feasibility of
    extended-release quetiapine fumarate (quetiapine XR) for the treatment of patients with either a primary anxiety
    disorder or a mood disorder with comorbid anxiety symptoms compared to a placebo, as an adjunct to
    antidepressant therapy.
    Methods: Thirty-nine patients with a diagnosis of a primary anxiety disorder or a mood disorder with comorbid
    anxiety symptoms were enrolled in this study. Patients with a stable dose of antidepressant therapy were
    randomized according to a 2:1 probability of receiving either quetiapine XR or a placebo adjunctive treatment for
    8 weeks. The efficacy was assessed by the Hamilton Anxiety Rating Scale (HAM-A) and the Clinical Global
    Impression of severity (CGI-S) score at baseline, week 1, 4, and 8.
    Results: A total of 35 patients were included in this intention-to treat (ITT) population for the efficacy analysis
    (quetiapine XR: 22 patients; placebo: 13 patients). At week 4, statistically significant differences were observed on
    both the HAM-A score (p = 0.003) and the CGI-S score (p = 0.025), favouring the quetiapine XR (−13.00 ± 4.14)
    compared to placebo (−6.63 ± 5.42). However, no statistically significant difference was observed between the two
    groups with regard to changes from the baseline to week 8 on the HAM-A score (p = 0.332) or the CGI-S score
    (p = 0.833).
    Conclusions: Augmentation of antidepressant treatment with quetiapine XR did not result in clinical improvement
    according to the outcome measure of anxiety using the HAM-A and CGI-S scores at week 8, among the patients
    with either a primary anxiety disorder or a mood disorder with comorbid anxiety symptoms. However, treatment
    with quetiapine XR as an adjunct to antidepressant therapy appeared to provide a short-term benefit at 4 weeks.
    Further study is needed with a larger sample size, randomized controlled design and control of the
    dosage prescribed.